Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome.

Abstract

INTRODUCTION:

Although current evidence suggests that initial dose of 200 mg/kg poractant alfa reduces mortality in the treatment of respiratory distress syndrome (RDS), these data were obtained in a highly heterogeneous group of patients and neither of them addressed mortality as primary outcome.

OBJECTIVE:

The aim of this study was to investigate the effects of poractant alfa and beractant on mortality when administered as early rescue surfactant therapy in very preterm infants.

METHODS:

We retrospectively evaluated preterm infants followed in our unit between May 2017 and November 2018 whose gestational age (GA) was ≤28 weeks and received surfactant within the first 2 hours of life. Morbidities and mortality rates were compared between infants who received initial doses of 200 mg/kg poractant alfa and 100 mg/kg beractant.

RESULTS:

Data from 200 infants who met the inclusion criteria were analyzed. There were 112 patients in the poractant alfa group and 88 patients in beractant group. Mean gestational age in these groups was 26 ± 2 and 25.8 ± 1.8 weeks (P = 0.45) and mean birth weight was 812 ± 243 and 840 ± 208 g (P = 0.39), respectively. The poractant alfa and beractant groups had similar rates of overall mortality (53.5% vs 56.8%), mortality in first 7 days (30.5% vs 25.8%), and beyond day 7 (16.4% vs 13.3%) (P > 0.05). There were no differences in the incidence of preterm morbidities among the two groups.

CONCLUSION:

We were unable to demonstrate the superiority of poractant in terms of mortality in very preterm infants with RDS. These findings need to be supported by multicenter, randomized controlled trials.

• Authors: Gülsüm Kadıoğlu Şimşek, Hayriye Gözde Kanmaz Kutman, Fuat Emre Canpolat, Şerife Suna Oğuz
• Journal: The clinical respiratory journal (Clin Respir J) Vol. 14 Issue 3 Pg. 285-290 (Mar 2020) ISSN: 1752-699X [Electronic] England
• PMID: 31814293 (Publication Type: Journal Article)
• Copyright: © 2019 John Wiley & Sons Ltd.

Chemical References

• Biological Products
• Phospholipids
• Pulmonary Surfactants
• poractant alfa
• beractant

Topics

• Biological Products (administration & dosage, therapeutic use)
• Birth Weight
• Bronchopulmonary Dysplasia (diagnosis, epidemiology)
• Case-Control Studies
• Female
• Gestational Age
• Humans
• Infant, Newborn
• Infant, Premature, Diseases (epidemiology, mortality)
• Male
• Mortality (trends)
• Phospholipids (administration & dosage, therapeutic use)
• Pulmonary Surfactants (administration & dosage, therapeutic use)
• Respiratory Distress Syndrome, Newborn (drug therapy, mortality)
• Retrospective Studies
• Treatment Outcome